Story perspectives

Study: Pemafibrate and Telmisartan Cut Liver Fat, Boost Glucose

10/7/2025

Summary

Story summary

Researchers at the University of Barcelona found that pemafibrate plus telmisartan reduce liver fat in models of metabolic dysfunction-associated steatotic liver disease (MASLD).
Telmisartan increases PCK1 protein levels, diverting metabolism from fat toward glucose.
Combination may lower cardiovascular risk in MASLD patients and supports repurposing as cost-effective.
Clinical studies are needed to confirm efficacy in humans and assess advanced MASLD.

1 of 1

Story summary

Researchers at the University of Barcelona found that pemafibrate plus telmisartan reduce liver fat in models of metabolic dysfunction-associated steatotic liver disease (MASLD).
Telmisartan increases PCK1 protein levels, diverting metabolism from fat toward glucose.
Combination may lower cardiovascular risk in MASLD patients and supports repurposing as cost-effective.
Clinical studies are needed to confirm efficacy in humans and assess advanced MASLD.